Johnson & Johnson (NYSE:JNJ) Shares Down 0.8%

Johnson & Johnson (NYSE:JNJGet Free Report)’s stock price was down 0.8% during trading on Friday . The stock traded as low as $148.05 and last traded at $148.49. Approximately 1,519,876 shares traded hands during mid-day trading, a decline of 79% from the average daily volume of 7,301,688 shares. The stock had previously closed at $149.70.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on JNJ. HSBC upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price target for the company from $169.00 to $170.00 in a research report on Thursday, April 18th. Royal Bank of Canada restated an “outperform” rating and set a $175.00 price target on shares of Johnson & Johnson in a research report on Wednesday. Morgan Stanley decreased their price objective on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a report on Wednesday, April 17th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Finally, Bank of America lowered their price target on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $175.86.

View Our Latest Research Report on JNJ

Johnson & Johnson Stock Down 1.2 %

The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.94 and a current ratio of 1.17. The stock has a market cap of $356.12 billion, a PE ratio of 9.26, a price-to-earnings-growth ratio of 2.55 and a beta of 0.55. The company’s 50-day moving average price is $151.53 and its 200 day moving average price is $155.07.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.64 by $0.07. The business had revenue of $21.38 billion for the quarter, compared to the consensus estimate of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The company’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period last year, the firm earned $2.68 earnings per share. As a group, analysts forecast that Johnson & Johnson will post 10.64 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be given a dividend of $1.24 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.35%. The ex-dividend date of this dividend is Monday, May 20th. Johnson & Johnson’s payout ratio is presently 30.92%.

Institutional Investors Weigh In On Johnson & Johnson

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Stableford Capital II LLC raised its stake in Johnson & Johnson by 4.3% during the 3rd quarter. Stableford Capital II LLC now owns 14,612 shares of the company’s stock valued at $2,177,000 after purchasing an additional 596 shares during the period. Abundance Wealth Counselors purchased a new position in Johnson & Johnson during the third quarter valued at $1,525,000. Kelman Lazarov Inc. increased its holdings in Johnson & Johnson by 6.9% in the 3rd quarter. Kelman Lazarov Inc. now owns 4,409 shares of the company’s stock valued at $687,000 after acquiring an additional 284 shares during the last quarter. Wolff Financial Management LLC purchased a new stake in Johnson & Johnson in the 3rd quarter worth $211,000. Finally, Bogart Wealth LLC grew its position in shares of Johnson & Johnson by 1.9% during the third quarter. Bogart Wealth LLC now owns 30,627 shares of the company’s stock valued at $4,770,000 after purchasing an additional 581 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

About Johnson & Johnson

(Get Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Further Reading

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.